
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Zimmer Biomet (ZBH) faces margin contraction despite earnings beat. Explore the Paragon 28 acquisition, marketing strategies, and leadership changes impacting this medical device leader.
Zimmer Biomet (ZBH) navigates Q4 earnings, strategic shifts, and market headwinds. Paragon 28 acquisition and GLP-1 impacts analyzed. Actionable insights provided.
Zimmer Biomet's Q4 earnings beat estimates, but currency headwinds and margin compression loom. A deep dive into ZBH's strategic moves and market outlook.
Zimmer Biomet (ZBH) balances Q4 earnings with 2025 profit concerns. Strategic initiatives aim to drive growth, but currency headwinds and margin pressures persist.
Zimmer Biomet’s Q4 2024 earnings beat estimates with solid revenue growth but concerns over margin contraction, a strong dollar, and short‐term EPS dilution raise questions for 2025.